
Abi Vijenthira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/176510/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Use of Virtual Care in Patients with Hematologic Malignancies: A Scoping Review. Current Oncology, 2022, 29, 892-900.	2.2	9
2	Multiâ€national survey of transfusion experiences and preferences of patients with myelodysplastic syndrome. Transfusion, 2022, 62, 1355-1364.	1.6	12
3	Frailty in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Receiving Curative-Intent Therapy: A Population-Based Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 635-642.e9.	4.9	6
4	Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy. Bone Marrow Transplantation, 2021, 56, 2400-2409.	2.4	7
5	Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Advances, 2021, 5, 2624-2643.	5.2	70
6	The Use of Virtual Care in Patients with Hematologic Malignancies - a Scoping Review. Blood, 2021, 138, 1933-1933.	1.4	0
7	Development and Testing of a Lymphoma Clinical Trials Specific Frailty Index: A Secondary Analysis of the LY.12 Clinical Trial. Blood, 2021, 138, 4076-4076.	1.4	0
8	Are Novel Therapies Worth the Cost for Young Patients?: A Cost-Effectiveness Analysis of Frontline Therapies with or without Radiation for Early-Stage Unfavourable Hodgkin Lymphoma. Blood, 2021, 138, 662-662.	1.4	1
9	Virtual Care during the COVID-19 Pandemic Among Patients with Hematologic Malignancies - a Princess Margaret Cancer Centre Experience. Blood, 2021, 138, 838-838.	1.4	0
10	Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood, 2020, 136, 2881-2892.	1.4	479
11	Predictors of intensive care unit admission in patients with hematologic malignancy. Scientific Reports, 2020, 10, 21145.	3.3	11
12	Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study. Lancet Haematology,the, 2020, 7, e146-e156.	4.6	19
13	Frailty Is Associated with Increased One-Year Mortality in Patients with Newly Diagnosed Diffuse Large-B-Cell Lymphoma: A Population-Based Study. Blood, 2020, 136, 34-37.	1.4	1
14	Outcomes of Adult and Pediatric Patients with Hematologic Malignancies and COVID-19: A Systematic Review and Meta-Analysis of 1847 Patients. Blood, 2020, 136, 39-41.	1.4	0
15	An Implementation Guide to Promote Sleep and Reduce Sedative-Hypnotic Initiation for Noncritically Ill Inpatients. JAMA Internal Medicine, 2019, 179, 965.	5.1	25
16	Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naÃ ⁻ ve patients. Leukemia and Lymphoma, 2019, 60, 2576-2579.	1.3	0
17	The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study. Leukemia Research, 2019, 76, 76-81.	0.8	9
18	Cost-Effectiveness and Cost-Utility Analysis of ABVD Versus Beacopp in the Treatment of Advanced-Stage Hodgkin Lymphoma. Blood, 2018, 132, 2248-2248.	1.4	1

#	Article	IF	CITATIONS
19	ABVD Versus Combination Baseline Beacopp/Escalated Beacopp in the Treatment of Newly Diagnosed Advanced-Stage Hodgkin Lymphoma: A Decision Analysis. Blood, 2016, 128, 1183-1183.	1.4	1
20	ls Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab NaÃ-Ve Patients?. Blood, 2016, 128, 1795-1795.	1.4	0